Results - Announcements
Vivanza Biosciences Ltd share price inched up 3.50% to Rs 1.48 after the company's net profit slipped by 6.67% to Rs 0.14 crore, while revenue from operations increased sharply by 22.82% to Rs 11.41 crore in Q2FY27 over Q2FY26.
The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.82 lakh crore, easing 5.54%. It has marginally improved by 2.89% over last one week and crept higher by 3.43% in last one month while the market capitalization of Vivanza Biosciences Ltd has eased by 3.90% and 21.69% in the same period respectively.
Profit before tax (PBT) of Vivanza Biosciences Ltd stood at Rs 0.17 crore in Q2 FY27, tanking 69.64% year-on-year, and slipping 5.56% quarter-on-quarter. EBITDA came in at Rs 0 crore, plunging by 54.24% YoY and tumbling by 161.36% sequentially.
Total expenses rose by 19.32% to Rs 11.18 crore in Q2FY27 over Q2FY26. During the quarter, employee benefits expense was at Rs 0.1 crore, remaining flat YoY.
For FY26, revenue from operations soared by 1462.13% to Rs 115.91 crore, while net profit witnessed a sharp fall of 158.21% to Rs 0.39 crore, compared to previous FY. EBITDA tanked by 142% to Rs 0.62 crore, and PBT plunged by 180.60% to Rs 0.54 crore compared to previous FY.
The company's consolidated net cash flow from operating activities stood at Rs 2.58 crore in FY26, as against Rs 2.5 crore in FY25.
Vivanza Biosciences Ltd nosedived by 24.87% in last one year, underperforming the benchmark BSE Sensex which has slipped by 2.74% during the same period.